Ledyard National Bank Raises Position in Novo Nordisk A/S (NYSE:NVO)

Ledyard National Bank raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.1% in the fourth quarter, Holdings Channel reports. The fund owned 4,148 shares of the company’s stock after buying an additional 200 shares during the period. Ledyard National Bank’s holdings in Novo Nordisk A/S were worth $429,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. CNB Bank acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $26,000. Pacific Center for Financial Services raised its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Valued Wealth Advisors LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $28,000. Copeland Capital Management LLC raised its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after acquiring an additional 141 shares during the last quarter. Finally, Bell Investment Advisors Inc raised its holdings in Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Trading Up 0.7 %

NYSE NVO traded up $0.84 on Tuesday, reaching $127.72. The stock had a trading volume of 4,923,952 shares, compared to its average volume of 4,762,776. The firm has a market capitalization of $573.15 billion, a price-to-earnings ratio of 47.77, a P/E/G ratio of 2.12 and a beta of 0.41. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The stock has a fifty day moving average price of $126.92 and a two-hundred day moving average price of $112.40.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s payout ratio is 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.